Avoid common mistakes on your manuscript.
Erratum zu:
Urologie 2023
Die Tab. 3 enthält einen Fehler. Korrekt muss es in Zeile 4 heißen Sacituzumab Govitecan + Pembrolizumab [17] (NCT03547973, TROPHY-U-01, Kohorte 3). Wir bitten die Korrektur zu beachten und den Fehler zu entschuldigen.
Der Originalbeitrag wurde korrigiert.
Literatur
Rosenberg JE et al (2022) LBA73—Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). Ann Oncol 33:S808–S869
Zhou L et al (2022) Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol 40(6):515–515
Galsky MD et al (2022) Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J Clin Oncol 40(6):438–438
Grivas P et al (2022) TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. J Clin Oncol 40(6):434–434
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grimm, MO., Foller, S., Leeder, M. et al. Erratum zu: Antikörper-Wirkstoff-Konjugate als neues Wirkprinzip in der Uroonkologie. Urologie 62, 1095 (2023). https://doi.org/10.1007/s00120-023-02178-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-023-02178-2